cancer cell

Recent News

January 2018

Dr Fiona Dempsey (Director of Scientific Operations, aTen Therapeutics) joined Rose Maciewicz from AstraZeneca to address Glasgow University postdocs about industry careers.

November 2017

aTen Therapeutics’ Tina Flatau facilitates panel discussion on “Patient Centricity” at Pharma Integrates 2017 in London

Tensinomab product logo

aTen Therapeutics’ lead candidate Tensinomab is a humanised single chain variable fragment (scFv) monoclonal antibody.

Tensinomab selectively modulates the angiotensin II Type 1 receptor (AT1R) which plays a central role in major diseases. In non-clinical testing, we have shown that Tensinomab has potential to treat a broad range of serious medical conditions.

Our lead development programme uses Tensinomab to treat primary cancers and protect against developing metastases, a major cause of cancer death.

In parallel, our development team is researching ATIR modulation to treat other major diseases.

There is mounting evidence demonstrating Tensinomab’s potential to become a significant new therapeutic agent and the aTen Therapeutics team is committed to exploring and exploiting this potential to extend and improve lives.

info@atentherapeutics.com

© aTen Therapeutics 2018. All rights reserved